Method of Producing Fully Carbamylated Erythropoietin
AssigneeThe Kenneth S. Warren Institute, Inc.
InventorsMichael Brines, Anthony Cerami, Carla Hand, Qiao-wen Xie
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Kenneth S. Warren Institute, Inc.
InventorsMichael Brines, Anthony Cerami, Carla Hand, Qiao-wen Xie
Estimating the term…
The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 μg/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay. Additionally, the invention is related to pharmaceutical compositions containing carbamylated erythropoietins of the invention and the use of the pharmaceutical compositions for the treatment of conditions and diseases of excitable tissues.
A method for producing a carbamylated erythropoietin having less that about 10% free primary amines on the lysines and the N-terminal amino acids wherein the method comprises contacting an amount of erythropoietin at a concentration of less than 4 mg/ml, with a concentration of about 0.05 M to 2 M potassium cyanate, with a concentration of about 0.05 M to 0.5 M sodium borate buffer pH 7-10, at a temperature of about 30 to 38° C. for a period of about 1 to 24 hours wherein the carbamylated erythropoietin is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 μg/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay.
The method of claim 18 wherein the erythropoietin is asialoerythropoietin.
A pharmaceutical composition comprising a non-toxic therapeutically effective amount of a carbamylated erythropoietin wherein the carbamylated erythropoietin has less than about 10% free primary amines on the lysines and the N-terminal amino acids is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 μg/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.